“同源重组修复缺陷可能预测神经内分泌肿瘤肽受体放射性核素治疗的反应”一文更新。
Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors".
机构信息
Mayo Clinic, Rochester, MN, USA.
Mayo Clinic, Phoenix, AZ, USA.
出版信息
Oncologist. 2022 Jun 8;27(6):e534-e535. doi: 10.1093/oncolo/oyac068.
Abstract
This letter to the editor reports subsequent rechallenge with peptide receptor radionuclide therapy (PRRT) in a patient with pancreatic neuroendocrine tumor bearing BRCA1 mutation previously treated with PRRT.
摘要
这封给编辑的信报告了一例先前接受过肽受体放射性核素治疗 (PRRT) 的伴有 BRCA1 突变的胰腺神经内分泌肿瘤患者再次接受 PRRT 治疗的情况。
Zotero 插件